BACKGROUND: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). METHODS: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. RESULTS: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p<0.001), but positively with FT4 (r=0.696, p < 0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. CONCLUSIONS: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps. 2020 Olgica Mihaljević, Snežana Živančević-Simonović, Aleksandra Lučić-Tomić, Irena Živković, Rajna Minić, Ljiljana Mijatović-Teodorović, Zorica Jovanović, Marija Anđelković, Marijana Stanojević-Pirković, published by CEON/CEES.
BACKGROUND: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). METHODS: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. RESULTS: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p<0.001), but positively with FT4 (r=0.696, p < 0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. CONCLUSIONS: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps. 2020 Olgica Mihaljević, Snežana Živančević-Simonović, Aleksandra Lučić-Tomić, Irena Živković, Rajna Minić, Ljiljana Mijatović-Teodorović, Zorica Jovanović, Marija Anđelković, Marijana Stanojević-Pirković, published by CEON/CEES.
Entities:
Keywords:
beta-cross-laps; bone metabolism; osteocalcin; sclerostin; thyroid dysfunction
Authors: Patrick J O'Shea; Dong Wook Kim; John G Logan; Sean Davis; Robert L Walker; Paul S Meltzer; Sheue-yann Cheng; Graham R Williams Journal: J Biol Chem Date: 2012-03-22 Impact factor: 5.157
Authors: Elizabeth Grethen; Kathleen M Hill; RoseMarie Jones; Brenda M Cacucci; Christine E Gupta; Anthony Acton; Robert V Considine; Munro Peacock Journal: J Clin Endocrinol Metab Date: 2012-02-22 Impact factor: 5.958
Authors: B García-Fontana; S Morales-Santana; M Varsavsky; A García-Martín; J A García-Salcedo; R Reyes-García; M Muñoz-Torres Journal: Osteoporos Int Date: 2013-08-01 Impact factor: 4.507
Authors: T Kuber Sampath; Petra Simic; Rebecca Sendak; Natasa Draca; Ann E Bowe; Stephen O'Brien; Susan C Schiavi; John M McPherson; Slobodan Vukicevic Journal: J Bone Miner Res Date: 2007-06 Impact factor: 6.741
Authors: Zhanna E Belaya; Galina A Melnichenko; Ljudmila Y Rozhinskaya; Valentin V Fadeev; Tatjana M Alekseeva; Olga K Dorofeeva; Natalja I Sasonova; Galina S Kolesnikova Journal: Hormones (Athens) Date: 2007 Jan-Mar Impact factor: 2.885
Authors: A H van Lierop; A W van der Eerden; N A T Hamdy; A R Hermus; M den Heijer; S E Papapoulos Journal: J Clin Endocrinol Metab Date: 2012-07-27 Impact factor: 5.958
Authors: Etsuko Abe; Russell C Marians; Wanqin Yu; Xue Bin Wu; Takao Ando; Yanan Li; Jameel Iqbal; Leslie Eldeiry; Gopalan Rajendren; Harry C Blair; Terry F Davies; Mone Zaidi Journal: Cell Date: 2003-10-17 Impact factor: 41.582